Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.48 |
| ▸ | NMT1 | P30419 | 6/20 | 0.42 |
| ▸ | NMT2 | O60551 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26169977 | 0.81 | CPB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL26904745 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL3214045 | 0.78 | CPB2 (0.76) | CPB2 | |
| SCHEMBL23685556 | 0.76 | KMT2A (0.39) | NMT1NMT2 | |
| SCHEMBL24916226 | 0.76 | CPB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL29619511 | 0.74 | CPB2 (0.58) | CPB2NMT1NMT2 | |
| SCHEMBL26169926 | 0.74 | CPB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL26174195 | 0.73 | CPB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 | |
| SCHEMBL30657894 | 0.73 | CPB2 (0.57) | CPB2 | |
| SCHEMBL26172465 | 0.73 | CPB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |